New cell therapy aims to supercharge Kids' immune cells after transplant
Disease control
Not yet recruiting
This early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…
Phase: PHASE1 • Sponsor: Michel Duval • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC